The most common adverse events in the lenvatinib group were hypertension (67.8%), diarrhea (59.4%), fatigue (59%), decreased appetite (50.2%), decreased weight (46.4%), and nausea (41%)
Along with the Semaglutide GLP-1 treatment, Dr
Anecdotally, health systems have closed hospital-based metabolic bariatric surgery programs due to decreased demand, but empirical data on the association of increased prescribing of GLP-1 [receptor agonists] with use of metabolic bariatric surgery is unavailable, to our knowledge, Kevin Lin, BA, from Harvard Medical School, and colleagues wrote in JAMA Network Open
What are Common GLP-1 Side Effects
However, stopping semaglutide often leads to weight regain within 12 months if lifestyle changes aren't maintained alongside medication
Discover what you really get for your investmentand why medically supervised weight loss may be worth every penny